• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.

作者信息

Bhuyan Prakash, Medin Jennie, da Silva Hugo Gomes, Yadavalli Madhavi, Shankar Nirmal Kumar, Mullerova Hana, Arnold Matthew, Nord Magnus

机构信息

Global Clinical Development Late R&I, AstraZeneca, Gaithersburg, MD, USA.

Global Medical BioPharmaceuticals, AstraZeneca, Gothenberg SE431 83, Sweden.

出版信息

Lancet. 2021 Aug 14;398(10300):577-578. doi: 10.1016/S0140-6736(21)01693-7. Epub 2021 Jul 27.

DOI:10.1016/S0140-6736(21)01693-7
PMID:34329583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9753120/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4845/9753120/a28e0a8668a7/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4845/9753120/a28e0a8668a7/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4845/9753120/a28e0a8668a7/fx1_lrg.jpg

相似文献

1
Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.第二次接种AZD1222后出现极罕见的血栓形成伴血小板减少症：一项全球安全性数据库分析
Lancet. 2021 Aug 14;398(10300):577-578. doi: 10.1016/S0140-6736(21)01693-7. Epub 2021 Jul 27.
2
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.接种 AZD1222（ChAdOx1 nCov-19）疫苗后发生的血栓伴血小板减少症：病例特征和关联。
Vaccine. 2022 Sep 9;40(38):5585-5593. doi: 10.1016/j.vaccine.2022.08.007. Epub 2022 Aug 19.
3
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.ChAdOx1新冠疫苗接种后的血栓形成和血小板减少症
N Engl J Med. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882. Epub 2021 Apr 9.
4
Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.AZD1222 和 BNT162b2 新冠疫苗接种与一线人员血栓栓塞和血小板减少事件的关联：一项回顾性队列研究。
Ann Intern Med. 2022 Apr;175(4):541-546. doi: 10.7326/M21-2452. Epub 2022 Feb 1.
5
Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination.接种AZD1222（ChAdOx1 nCoV-19）疫苗后血栓性血小板减少症（TTS）病例的地理分布。
Lancet Glob Health. 2022 Jan;10(1):e33-e34. doi: 10.1016/S2214-109X(21)00545-3.
6
Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后血栓形成伴血小板减少综合征
Clin Adv Hematol Oncol. 2021 Jul;19(7):446-449.
7
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.新型冠状病毒病疫苗诱导的免疫性血栓性血小板减少症的血栓形成模式和临床结局：系统评价和荟萃分析。
Int J Infect Dis. 2022 Jun;119:130-139. doi: 10.1016/j.ijid.2022.03.034. Epub 2022 Mar 24.
8
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.在 3 个北欧国家分析 AZD1222、BNT162b2 和 mRNA-1273 新冠疫苗接种后的血栓栓塞和血小板减少事件。
JAMA Netw Open. 2022 Jun 1;5(6):e2217375. doi: 10.1001/jamanetworkopen.2022.17375.
9
VITT and Second Doses of Covid-19 Vaccine.疫苗诱导的免疫性血小板减少症（VITT）与新冠病毒疾病-19疫苗第二剂
N Engl J Med. 2022 Jan 6;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22.
10
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome.COVID-19 疫苗与血栓性血小板减少综合征。
Expert Rev Vaccines. 2021 Aug;20(8):1027-1035. doi: 10.1080/14760584.2021.1949294. Epub 2021 Jul 8.

引用本文的文献

1
Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.2011年至2022年血栓性血小板减少综合征的流行病学：英文哨点网络队列研究。
Drug Saf. 2025 Oct;48(10):1161-1175. doi: 10.1007/s40264-025-01566-1. Epub 2025 Jul 31.
2
Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study.国药集团BBIBP-CorV疫苗接种者接种AZD1222疫苗加强针后不良事件的监测与主动监测：一项队列研究
BMC Public Health. 2025 Feb 17;25(1):650. doi: 10.1186/s12889-025-21805-5.
3
Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia.

本文引用的文献

1
Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries.新冠病毒疾病疫苗安全性监测特别关注的五种血栓形成伴血小板减少综合征的背景发病率：2017年至2019年的发病率以及六个欧洲国家3860万人的患者资料。
Pharmacoepidemiol Drug Saf. 2022 May;31(5):495-510. doi: 10.1002/pds.5419. Epub 2022 Feb 27.
2
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.辉瑞-生物科技疫苗和牛津-阿斯利康疫苗对英格兰老年人新冠病毒相关症状、住院及死亡率的有效性：检测阴性病例对照研究
BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088.
3
疫苗诱导的免疫性血栓性血小板减少症后再次接种严重急性呼吸综合征冠状病毒2疫苗
J Clin Med. 2024 Sep 14;13(18):5462. doi: 10.3390/jcm13185462.
4
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.AZD1222（ChAdOx1 nCoV-19）的长期安全性和免疫原性：一项3期研究的2年随访
Vaccines (Basel). 2024 Aug 3;12(8):883. doi: 10.3390/vaccines12080883.
5
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.Ad26.COV2.S疫苗接种后刺突蛋白的生物分布不太可能在疫苗诱导的免疫性血栓性血小板减少症中起作用。
Vaccines (Basel). 2024 May 20;12(5):559. doi: 10.3390/vaccines12050559.
6
Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.血栓性血小板减少性综合征伴 COVID-19 疫苗接种后凝血和促炎途径的激活。
Nat Commun. 2023 Oct 23;14(1):6703. doi: 10.1038/s41467-023-42559-x.
7
Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines.关于第二剂BNT162b2和ChAdOx1新冠疫苗后出血和血栓形成事件的情况说明
Lancet Reg Health Eur. 2023 Jul 31;32:100708. doi: 10.1016/j.lanepe.2023.100708. eCollection 2023 Sep.
8
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea.2019冠状病毒病疫苗的安全性监测：2021年2月26日至2022年6月4日，大韩民国
Clin Exp Pediatr. 2023 Oct;66(10):415-423. doi: 10.3345/cep.2022.00815. Epub 2023 Jun 13.
9
Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing.全血促凝血血小板流式细胞术检测肝素诱导的血小板减少症（HIT）和疫苗诱导的免疫性血栓性血小板减少症（VITT）的方案。
Methods Mol Biol. 2023;2663:441-461. doi: 10.1007/978-1-0716-3175-1_29.
10
Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.成人新型冠状病毒刺突蛋白三聚体亚单位疫苗（SCB-2019）的 6 个月安全性随访：一项 2/3 期、双盲、随机研究。
Vaccine. 2023 Mar 24;41(13):2253-2260. doi: 10.1016/j.vaccine.2023.02.018. Epub 2023 Feb 10.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
4
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.腺病毒载体新冠疫苗（AZD1222）对 202012/01 关注变异株（B.1.1.7）的疗效：一项随机对照试验的探索性分析。
Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30.
5
Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor.新型冠状病毒2型感染中的凝血异常：组织因子过表达
Thromb J. 2020 Dec 15;18(1):38. doi: 10.1186/s12959-020-00250-x.